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Purpose: Prostatic carcinoma is a common and growing public health problem. Histological evaluation is fairly adequate for 
assessing tumor differentiation, but tumor proliferative activity is difficult to measure. Increasing evidence suggests that the factors 
controlling cell cycle progression also modulate the rate of ribosome biogenesis. Despite the influence of cyclin D1 and argyrophilic 
nuclear organizer region (AgNOR) on prostate cancer proliferation, few studies have evaluated the diagnostic importance of these 
markers. Therefore, the present study was carried out to analyze the diagnostic value of the proliferative markers cyclin D1 and AgNOR 
in various prostatic lesions and to determine whether any association or relation between these markers and different Gleason grades 
exists.
Methods:  A total 50 cases of various prostatic lesions were studied. Tumor grade, AgNOR staining, and cyclin D1 expression were 
evaluated in all cases. Correlations between the intensity and differential localization of these markers and Gleason grades were 
evaluated.
Results: The mean AgNOR count in cases of prostatic intraepithelial neoplasia was high compared with cases of benign prostatic 
hyperplasia (BPH) but lower than that of carcinoma cases. The intensity of cyclin D1 expression was high in carcinoma. A total of 
14 cases (46.67%) showed strong positivity. No  significant correlation was found  between  the intensity of cyclin D1 expression, 
AgNOR count, and  histologic grades of prostatic carcinoma, whereas a significant correlation was observed  between intensity and 
percentage expression of cyclin D1 in BPH and carcinoma (P<0.01). Nuclear as well as cytoplasmic positivity was seen among various 
grades of carcinoma.
Conclusions: AgNOR count and cyclin D1 may be helpful in distinguishing between BPH and carcinoma of the prostate but may 
not be used as reliable indicators of the grade of prostatic adenocarcinoma because of overlapping values in various grades. However, 
further studies on larger samples are required to elucidate the role of these markers in identification of premalignant lesions. 
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INTRODUCTION
Prostatic disease is responsible for significant morbidity and 
mortality in men throughout the world. The diagnosis of 
prostate adenocarcinoma is often challenging. Whereas his-
tological evaluation is fairly adequate for assessing differen-
tiation, tumor proliferative activity is difficult to measure. The 
identification of molecular events underlying cell transforma-
tion may expand our understanding of the natural history 
of the disease. Nucleolar organizer regions (NORs) are seg-
ments of metaphase chromosomes where ribosomal genes 
are located and which correspond to secondary constrictions 
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subjected to careful and detailed gross examination. Tissue 
sections were fixed in 10% formalin and embedded in paraf-
fin and were used for microscopic study. Sections 4 to 5 µ 
thick were prepared and stained routinely with hematoxylin 
and eosin (H&E) [6]. These sections were then studied under 
a light microscope and were classified as benign or malignant 
lesions. Special stains like van Gieson, periodic acid-Schiff, 
Masson’s trichrome, and reticulin were used whenever re-
quired for histopathological diagnosis.
 Silver staining for AgNOR and immunohistochemistry: 
AgNOR staining was performed according to the guidelines 
of the “International Committee on AgNOR Quantitation” [7]. 
AgNOR was observed and counted as black dots in the nuclei 
of at least 100 cells by using a 100 ×  oil immersion objective 
and the average was calculated [8].
 Immunohistochemistry was performed by the peroxidase-
antiperoxidase method [9]. Positive and negative controls 
were run simultaneously. Tissue from the tonsil (epithelium) 
was used as a positive control. A negative control was made 
by substituting primary antibody with antibody of irrelevant 
specificity.
 Immunohistochemistry evaluation: Cyclin D1 staining in-
tensity was assessed as follows [10]:
• 0 (absent)
• 1– (weak/focal < 10% of sample)
• 1+ (weak intensity < 25% of sample)
• 2+ (moderate intensity 25%–50% of sample)
• 3+ (strong intensity > 50% of sample)
 The data thus obtained were analyzed in the form of mean 
AgNOR count/cell and cyclin D1 expression in all benign 
and malignant cases including various grades of prostatic 
carcinoma. Cyclin D1 was assessed in the form of percentage 
of expression and staining intensity and was scored as 0, 1–, 
1+, 2+, and 3+ as well as by the pattern of expression whether 
nuclear, cytoplasmic, or both [11,12].
 Statistical analysis: The results thus obtained were inter-
preted and correlated statistically. Comparison between mul-
tiple groups was made by using Student t-test, chi-square test, 
and analysis of varivance test, whichever was appropriate. A 
value of P < 0.05 was taken as significant and < 0.01 was taken 
as highly significant, whereas P-values of > 0.05 were taken as 
nonsignificant.
RESULTS
A total of 50 cases were used in the present study, which in-
[1]. These structures contain all necessary components for 
rRNA synthesis and are the sites where the transcription of ri-
bosomal genes occurs [2]. The silver-stained NORs are called 
argyrophilic nucleolar organizer region associated proteins 
(AgNORs). AgNORs in normal cells are usually tightly aggre-
gated within one or two nuclei, thus making individual Ag-
NORs indiscernible. An increase in the mean AgNOR count 
of a cell population could be the result of a defect in nucleolar 
aggregation, association, ploidy, or increased transcriptional 
activity [3,4]. Theoretically, a neoplastic cell population could 
show any or all of the above defects and therefore demon-
strate an increased AgNOR count. Several studies have shown 
that AgNOR frequency within nuclei is significantly higher in 
malignant cells than in normal, reactive, or benign neoplastic 
cells. AgNOR expression is directly related to the ribosome 
biosynthesis rate, which, in proliferating cells, is directly re-
lated to the length of the cell cycle. The shorter the cell cycle, 
the greater the synthesis of rRNA for each time unit and, 
therefore, the greater the quantity of AgNOR present in the 
nucleolus. Thus, the AgNOR value was thought to be a mea-
sure of the rate of cell proliferation [1].
 Cyclin D1 is an amino acid that is expressed in the G1 phase 
of the cell cycle and that has an important role in regulating 
the cell cycle and cancer progression. Its over-expression is 
believed to play an important role in both the tumorigenesis 
and grading of many cancers, including prostatic carcinoma. 
There is increasing evidence that the factors controlling cell 
cycle progression also modulate the rate of ribosome biogen-
esis. In prostatic cancer, cyclin D1 acts as a critical regulator of 
androgen-dependent transcription and cell cycle progression 
[5].
 Despite the influence of cyclin D1 and AgNOR on prostate 
cancer proliferation, few studies have evaluated the diagnos-
tic importance of these markers. Therefore, the present study 
was carried out to analyze the diagnostic value of the prolif-
erative markers cyclin D1 and AgNOR in benign and malig-
nant lesions of the prostate and also to prove or disprove an 
association or relation between these markers and different 
Gleason grades.
MATERIALS AND METHODS
Clinical and pathological data: This prospective study was 
carried out in the Department of Pathology, Pandit Bhagwat 
Dayal Sharma Post Graduate Institute of Medical Sciences, 
Rohtak, India. A total of 50 cases of prostatic biopsies were tak-
en for study. Brief clinical data were noted from case records.
 Histopathological evaluation: All prostatic specimens were 
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of <0.01. Of the BPH cases, the maximum number of cases 
(7) showed focal positivity (38.88%), followed by absence of 
positivity and weak positivity (5 cases each). One case showed 
moderate positivity. No case showed strong positivity. Among 
two cases of PIN, one showed moderate positivity and the 
other showed strong positivity.
 Of the carcinoma cases, the maximum number of cases 
(14, or 46.67%) showed strong positivity, followed by moder-
ate positivity in 10 cases (33.33%), weak positivity in 5 cases 
(16.67%), and focal positivity in 1 case (3.33%). Absence of 
cyclin D1 expression was not noted in any case. 
 There was a statistically significant difference in intensity 
and percentage of expression of cyclin D1 between BPH and 
carcinoma (P < 0.01). The correlation of cyclin D1 expression 
with histologic grading in prostatic carcinoma is presented in 
Table 1.
3. Altered cyclin D1 expression
Of the BPH cases, 13 showed cyclin D1 expression, of which 
8 cases showed only nuclear positivity and 5 cases showed 
both nuclear and cytoplasmic positivity. Both cases of PIN 
showed nuclear as well as cytoplasmic positivity. Of the carci-
noma cases, 24 cases showed both nuclear and cytoplasmic 
positivity, whereas 2 cases showed cytoplasmic and 4 cases 
showed nuclear positivity only. The localization of cyclin D1 
expression in various grades of prostatic carcinoma is shown 
in Table 2  and Figs. 1-4. 
DISCUSSION
Prostate cancer is an important growing health problem with 
an often unpredictable course that presents a diagnostic chal-
lenge to urologists, radiologists, and pathologists. The tumor 
is dependent on androgen for growth and survival. Androgen 
elicits its biological effect through activation of the androgen 
receptor. Upon ligand binding, the activated receptor stimu-
lates a gene expression program that induces cellular prolif-
eration. Androgen induces accumulation of D type cyclins, 
cluded 18 cases (36%) of benign prostatic hyperplasia (BPH), 
2 cases (4%) of prostatic intraepithelial neoplasia (PIN), and 
30 cases (60%) of carcinoma. The majority of specimens were 
collected by needle biopsy (68%), followed by transurethral 
resection of the prostate (24%) and prostatectomy (8%). The 
age of the patients ranged from 46 to 95 years with a class in-
terval of 5 years and a mean age of 71.3 ± 10.16 years. The ma-
jority of cases (11 cases) were in the age group of 76–80 years, 
which formed 22% of the study group. Patients with carcino-
ma of the prostate were in the age group of 51–95 years with 
a mean age of 72.43+10.49 years. The maximum number of 
cases was in the age group of 76 to 80 years (7 cases), followed 
by the age group of 61–65 years (5 cases). 
 All foci of PIN were of high-grade PIN. The Gleason score 
was estimated in all cases by taking the primary grade (most 
prevalent) into consideration. Among the 30 cases of prostatic 
carcinoma, 17 cases (56.66%) were of intermediate grade, 9 
cases (30.0%) were of high grade, and only 4 cases (13.33%) 
were of low grade.
1. AgNOR quantitative distribution
The range of AgNOR dots per nucleus in BPH was 1.80–4.68 
with a mean of 3.03 ± 1.02. In cases of PIN, the range was 4.12–
4.96 with a mean of 4.54 ± 0.59. The corresponding figures for 
carcinoma were 2.06–7.74 with a mean of 5.37 ± 1.31. 
 The difference in mean number of AgNOR dots per nucle-
us between cases of BPH and cases of carcinoma was statisti-
cally significant (P < 0.001). The mean AgNOR count in cases 
of PIN was high compared with cases of BPH but was lower 
than in carcinoma cases. However, a statistical correlation 
could not be calculated because of the small number of cases.
 The range of AgNOR dots per nucleus in cases of low-grade 
carcinoma was 4.36–5.92 with a mean of 4.97 ± 0.67. On the 
other hand, the range in intermediate-grade carcinoma was 
2.06–7.74 with a mean of 5.25 ± 1.57. The range in high-grade 
carcinoma was 4.32–7.24 with a mean of 5.78 ± 0.94. The dif-
ference in mean number of AgNOR dots per nucleus between 
the three grades of carcinoma was statistically insignificant.
2. Cyclin D1 status
Cyclin D1 expression was assessed in various prostatic lesions 
by use of the peroxidase antiperoxidase immunohistochemi-
cal method. Nuclear and cytoplasmic staining intensity was 
assessed and scored semi quantitatively. There was no expres-
sion of cyclin D1 in 5 cases (27.77%) of BPH, whereas in PIN 
and carcinoma it was expressed in 100% of cases. There was 
a statistically significant difference in expression of cyclin D1 
between BPH and carcinoma cases, as indicated by a P-value 
Table 1. Correlation of cyclin D1 expression with histologic 
grading in prostatic carcinoma
Cyclin D1
   expression
Low grade 
(n=4)
Intermediate grade 
(n=17)
High grade
(n=9)
Absent 0 (0) 0 (0) 0 (0)
Focal 0 (0) 1 (5.88) 0 (0)
Weak 1 (25.0) 3 (17.65) 1 (11.11)
Moderate 2 (50.0) 5 (29.41) 3 (33.33)
Strong 1 (25.0) 8 (47.06) 5 (55.55)
Values are presented as number (%).
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which interact with and activate cyclin-dependent kinases 
to promote G1 progression during the cell cycle [10,13,14]. 
Tumor differentiation and proliferative activity are important 
predictors of biological behavior. Routine histopathological 
evaluation is fairly adequate for assessing differentiation. 
Tumor proliferative activity is difficult to measure, however. 
Silver staining for the NOR is reported to be useful for assess-
ing tumor proliferation. The present study was planned to 
analyze the AgNOR count and cyclin D1 expression in various 
prostatic lesions and to assess whether these can be useful 
in differentiating benign from malignant lesions and various 
grades of prostatic carcinomas. The study was also done to 
evaluate any correlation between the two markers.
 In prostate lesions, many studies have shown a significant-
ly increased proportion of proliferating cells in carcinoma 
compared with benign lesions, with the greatest proliferative 
indexes noted in high-grade carcinomas [15]. Thus, AgNOR 
counts increase with the aggressiveness of the tumor and are 
highest in high-grade prostatic carcinomas. In the present 
study, an increase in mean AgNOR count was noted from 
BPH to PIN and carcinomas. Furthermore, the mean AgNOR 
counts of carcinomas were significantly different from those 
of BPH. Similar observations were reported in other previous 
Fig. 1. Photomicrograph of benign prostatic hyperplasia speci-
men (H&E, ×200). Inset shows negative cyclin D1 expression 
and 4 to 5 AgNOR dots per nucleus.
Fig. 3. Photomicrograph of high-grade carcinoma specimen 
showing strong cyclin D1 positivity with inset revealing peri-
neural invasion (immunohistochemistry, ×200).
Fig. 2. Photomicrograph of prostatic intraepithelial neoplasia 
specimen (H&E, ×200). Inset shows moderate cyclin D1 positiv-
ity and 2 to 4 AgNOR dots per nucleus.
Fig. 4. Photomicrograph of high-grade carcinoma specimen 
revealing 5 to 7 AgNOR dots per nucleus (AgNOR, ×1,000).
Table 2. Localisation of cyclin D1 expression in various grades 
of prostatic carcinoma
Grade
Nuclear 
only
Cytoplasmic 
only
Both nuclear 
and cytoplasmic
Low grade (n=4) 0 0 4
Intermediate grade  (n=17) 2 2 13
High grade (n=9) 2 0 7
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Table 3. Table showing comparison of cyclin D1 positivity in prostatic lesions in different studies
Study
No. of cases Cyclin D1 positivity
Correlationa)
BPH Carcinoma BPH Carcinoma
Shiraishi et al. [24] - 66 - 20 (30.3) Absent
Drobnjak et al. [21] - 86 - 10 (11.6) Absent
Ozbek et al. [25] 25 30 * 30 (100) Present
Ueda et al. [22] 26 13 14 (53.8) 11 (84.6) -
Comstock et al. [10] 23 36 3 (13.0) 34 (94.4) Present
Present study 18 30 13 (72.2) 30 (100) Absent
Values are presented as number (%) unless otherwise indicated.
a)Correlation of cyclin D1 positivity with histologic grade. *Weak stromal staining.
studies [3,4].
 Hansen and Ostergard [3], however, reported overlapping 
counts. They concluded that, despite statistically significant 
differences, AgNOR counts are of no use for diagnosis of any 
single case. AgNOR typing, however, may contribute to a dif-
ferential diagnosis between benign and malignant lesions. 
Chiusa et al. [16] concluded that AgNOR counts not only re-
flect cell proliferation but also the degree of cellular differen-
tiation. Therefore, a combination of histological grading and 
AgNOR counts allows the stratification of low- and high-risk 
groups.
 Ghazizadeh et al. [17] also observed that the mean AgNOR 
count significantly increases with grade and clinical stage of 
tumor. They concluded that AgNOR counting may contribute 
to making a conventional diagnosis and prognosis of carci-
noma of the prostate. In our study, we observed overlapping 
AgNOR counts in various grades of carcinoma of the prostate, 
and the difference was not statistically significant.
 Ahsan et al. [18] also observed a significantly different count 
in nodular hyperplasia and carcinoma. They concluded that 
the AgNOR technique is rapid, simple, and reproducible, al-
though somewhat tedious and laborious. It can differentiate 
between nodular hyperplasia and carcinoma of the prostate 
on the basis of AgNOR count per cell. However, a small over-
lap in the range of counts along with the absence of a clear-cut 
gap between the counts in the two groups somewhat limits the 
importance of simple enumeration of AgNOR in an isolated 
case of nodular hyperplasia or carcinoma of the prostate.
 Cyclin D1, a cell regulatory protein that is considered a 
product of the cyclin D1 protooncogene, is an important 
regulator of the G1 to S phase transition of the cell cycle. It is 
believed to an play important role in both tumorigenesis and 
grading of many cancers, including prostatic carcinoma, if its 
expression is deregulated, mainly overexpressed [19]. Chen 
et al reported that overexpression of cyclin D1 increases cell 
growth and tumorigenicity in human prostate cancer [20].
 Several studies have been carried out in the past to see the 
expression of cyclin D1 in prostatic lesions. It has been ob-
served that cyclin D1 expression is enhanced in most local-
ized tumors compared with nonneoplastic epithelium, thus 
indicating that cyclin D1 is aberrantly regulated in prostate 
cancers. It has previously been shown through in vitro studies 
that cyclin D1 can influence androgen-dependent prostate 
cancer cell proliferation through its dual ability to modulate 
both CDK 4 and androgen receptor activity [10].
 Drobnjak et al. [21] concluded that cyclin D1 expression 
along with the proliferative index are associated with the clini-
copathological parameter of poor clinical outcome. However, 
no correlation was observed between cyclin D1 overexpres-
sion and either Gleason’s score, neo-adjuvant hormone treat-
ment, or PSA relapse.
 In 2001 Ueda et al. [22] found that 53.8% of cases of BPH 
and 84.6% of cases of prostatic carcinoma showed cyclin D1 
expression. These results indicate that cyclin D1 expression 
tends to increase in malignant prostate tissue.
 Fleischmann et al. [23] in 2010 found that in primary tu-
mors high nuclear cyclin D1 expression was significantly cor-
related with poor tumor differentiation and large nodal tu-
mor burden. In the present study, we studied the expression 
of cyclin D1 in 50 prostate samples. There was no expression 
of cyclin D1 in 5 cases (27.77%) of BPH, whereas in PIN and 
carcinoma it was expressed in 100% of cases.
 Our findings are in concordance with the results of previ-
ous studies indicating that cyclin D1 expression is seen with 
higher frequency in prostatic carcinoma (Table 3). We also 
observed that focal and weak staining may be seen in benign 
cases but that it never reaches a significant proportion as 
seen in carcinoma of the prostate. However, we observed no 
significant correlation of cyclin D1 expression with Gleason 
grade, which is similar to some studies [22,24] but in contrast 
with others [10,25]. The difference in the findings may be 
explained on the basis that most studies focused largely on 
nuclear cyclin D1, but common conclusions failed to emerge.
 In the present study, we also observed different patterns of 
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cyclin D1 expression. Comstock et al. [10] also found low or 
absent cyclin D1 expression in nonneoplastic tissue and in-
creased expression in most localized tumors. They observed 
different patterns of cyclin D1 expression in the tumor. Most 
tumors showed cytoplasmic restriction of cyclin D1, whereas 
high-grade tumors showed nuclear cyclin D1 staining. They 
concluded that cyclin D1 can be differentially expressed in 
prostatic cancer and that the status or localization of cyclin 
D1 expression is associated with meaningful changes in tu-
mor marker expression and proliferative indices [21].
 In conclusion, BPH and adenocarcinoma are common dis-
eases that account for considerable morbidity and mortality 
in the aging population. AgNOR count and cyclin D1 may be 
helpful in distinguishing between BPH and carcinoma of the 
prostate but may not be used as a reliable indicator of grading 
prostatic adenocarcinoma because of overlapping of values 
in various grades.  However, further studies on larger samples 
are required to elucidate the role of these markers in the iden-
tification of premalignant lesions. Also, the significance of dif-
ferential expression and localization of cyclin D1 needs to be 
evaluated further. There is a need for research on all aspects 
of this disease. The ultimate conquest of prostatic carcinoma 
will require substantial advances in our understanding of the 
cause of this tumor, further development and refinement of 
diagnostic techniques, and development of new therapeutic 
modalities for treatment of systemic disease. We can look for-
ward to further exciting developments in this important area 
of cancer cell research in the coming years. 
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